Prevalence of extended-spectrum beta-lactamase and class 1 integron integrase gene intl1 in Escherichia coli from thai patients and healthy adults

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 39, Issue 3, 2008, Pages 425-433

  Pongpech, Pintip ^a   Naenna, Penphun ^a   Taipobsakul, Yupin ^b   Tribuddharat, Chanwit ^b   Srifuengfung, Somporn ^a,b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 44949186546     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Babypadmini S, Appalaraju B. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli and Kiebsiella pneumoniae: prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol 2004; 22: 172-4,
2. Baraniak A, Fiett J, Hryniewicz W, Nordmann P, Gniadkowski N. Ceftazidime-hydrolysing CTX-M-15 extended-spectrum beta-lactamase (ESBL) in Poland. Antimicrob Agents Chemother 2002; 50: 1936-42.
3. Bell JM, Turnidge JD, Jones RN. Prevalence of extended-spectrum beta-lactamase-producing Enterobacter cloacae in the Asia-Pacific region; results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 3989-93.
4. st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
5. Cao V, Lambert T, Nhu DQ, et al. Distribution of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in Vietnam. Antimicrob Agents Chemother 2002; 46: 3739-43.
6. Chanawong A, Lulitanond A, Kaewkes W, Lulitanond V, Srigulbutr S, Homchampa P. CTX-M extended-spectrum beta-lactamases among clinical isolates of Enterobacteriaceae in a Thai university hospital. Southeast Asian J Trop Med Public Health 2007; 38: 493-500.
7. Chanawong A, M'Zali FH, Heritage J, Lulitanond A, Hawkey PM. SHV-12, SHV-5, SHV-2a and VEB-1 extended-spectrum beta-lactamases in Gram-negative bacteria isolated in a university hospital in Thailand. J Antimicrob Chemother 2001; 48: 839-52.
8. Dansuputra M. Detection and characterization of extended-spectrum beta-lactamases produced by Escherichia coli and Kiebsiella spp from clinical specimens of patients with infection in King Chulalongkorn Memorial Hospital. Bangkok: Chulalongkorn University, 2002. 106 pp. MS thesis.
9. Dejsirilert S, Apisarnthanarak A, Kijphati R, et al. The status of antimicrobial resistance in Thailand among gram-negative pathogens blood stream infection: NARST data, 2000-2003. [Cited 2004 Mar 20]. Available from: URL: http://narst.dmsc.moph.go.th
10. Eckert C, Gautier V, Hidri N, et al. Dissemination of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother 2004; 48: 1249-55.
11. Empel J, Filczak K, Mrowka A, Hryniewicz W, Livermore DM, Gniadkowski M. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J Clin Microbiol 2007; 45: 2829-34.
12. th ed. Washington, DC: American Society for Microbiology, 2003: 636-53.
13. Girlich D, Poirel L, Leelaporn A, et al. Molecular epidemiology of the integron-located VEB-1 extended-spectrum beta-lactamase in nosocomial enterobacterial isolates in Bangkok, Thailand. J Clin Microbiol 2001; 39: 175-82.
14. Goosen H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and Amp C - producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997 - 2004). Diagm Microbiol Infect Dis 2005; 53: 257-64.
15. Hirakata, Y, Matsuda J, Miyazaki Y, et al. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 2005; 52: 323-9.
16. Ingviya N, Hortiwakul R, Chayakul P, Thamjarungwong B. Prevalence and susceptibility patterns of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamases in Songklanagarind Hospital, Thailand. J Infect Dis Antimicrob Agents 2003; 20: 127-34.
17. Jacoby GA, Medeiros AA, O'Brien TF, Pinto ME, Jiang H. Broad-spectrum transmissible beta-lactamases. N Engl J Med 1988; 319: 723-4.
18. Kader AA, Kumar A. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital. Ann Saudi Med 2005; 25: 239-42.
19. Lee CH, Su LH, Tang YF, Liu JW. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 2006; 58: 1074-7.
20. Machado E, Canton R, Baguero F, et al. Integron content of extended spectrum beta-lactamase producing Escherichia coli strains over 12 years in a single hospital in Madrid, Spain. Antimicrob Agents Chemother 2005; 49: 1823-9.
21. Munday CJ, Xiong J, Li C, Shen D, Hawkey PM. Dissemination of CTX-M type beta-lactamases in Enterobacteriaceae isolates in the People's Republic of China. Int J Antimicrob Agents 2004; 23: 175-80.
22. Naas TL, Poirel B, Karim A, Nordmann P. Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum beta-lactamase VEB-1 in Pseudomonas aeruginosa. FEMS Microbiol Lett 1999; 176: 411-9.
23. Nathisuwan S, Burgess DS, Lewis JS. ESBLs: epidemiology, detection and treatment. Pharmacotherapy 2001; 21: 920-8.
24. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, fourteenth information supplement. Approved Standard NCCLS document M100-S14, 2004.
25. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-3.
26. Rasheed JK, Jay C, Metchock B, et al. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 1997; 41: 647-53.
27. Rossi F, Baquero F, Hsueh PR, et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006; 58: 205-10.
28. Ryoo NH, Kim EC, Hong SG, et al. Dissemination of SHV-12 and CTX-M-type extended-spectrum beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea. J Antimicrob Chemother 2005; 56: 698-702.
29. CTX-M-9. Antimicrob Agents Chemother 2002; 46: 2656-61.
30. Skurnik D, Menach AL, Zurakowski D, et al. Integron-associated antibiotic resistance and phylogenetic grouping of Escherichia coli isolates from healthy subjects free of recent antibiotic exposure. Antimicrob Agents Chemother 2005; 49: 3062-5.
31. Tribuddharat C. The mechanisms of antibiotic resistance in Pseudomonas aeruginosa. USA: Finch University of Health Sciences/The Chicago Medical School, 1999. 135 pp. Ph D thesis.
32. Tribuddharat C, Fennewald M. Integron-mediated rifampin resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 960-2.
33. Tribuddharat C, Fennewald MA. Resistance genes in multiply-resistant Pseudomonas aeruginosa clinical isolates from Siriraj Hospital. Siriraj Med J 2002; 54: 319-29.
34. Yu HS, Lee JC, Kang HY, et al. Changes in gene cassettes of class 1 integrons among Escherichia coli isolates from urine specimens collected in Korea during the last two decades. J Clin Microbiol 2003; 41: 5429-33.
35. Yu HS, Lee JC, Kang HY, et al. Prevalence of dfr genes associated with integrons and dissemination of dfrA17 among urinary isolates of Escherichia coli in Korea. J Antimicrob Chemother 2004; 53: 445-50.